Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lymdiaral (specifically Lymdiaral Injektopas) is a multi-component homeopathic and bioregulatory injectable preparation developed by NAMED S.r.l. in partnership with Pascoe. It is formulated as a complex remedy containing various homeopathic and phytotherapeutic ingredients, including *Taraxacum*, *Calendula*, *Arsenicum album*, and *Echinacea*, among others. The preparation is designed to support the lymphatic system by stimulating toxin drainage, inhibiting inflammation, and restoring hepatic function. It is primarily used for conditions such as lymphatism, chronic-recurrent inflammatory states, and edemas (post-traumatic, post-surgical, or radiation-related). In clinical research, it has been evaluated in Phase 4 pilot studies for the treatment of chronic venous-lymphatic insufficiency associated with panniculopathy-edema-fibrosclerotic (PEFS) via district intradermotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lymdiaral.